Research programme: CD70-expressing T cell immunotherapies - Immunicum

Drug Profile

Research programme: CD70-expressing T cell immunotherapies - Immunicum

Alternative Names: CD70-platform - Immunicum

Latest Information Update: 17 Feb 2014

Price : $50

At a glance

  • Originator Immunicum
  • Developer Immunicum; Uppsala University
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 17 Feb 2014 This research programme is available for licensing as of 17 Feb 2014. www.immunicum.com/
  • 31 Dec 2013 Preclinical trials in Cancer in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top